Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
| Hamilton Health Sciences Corporation | OTHER |
Not provided
Not provided
Not provided
Not provided
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm Cohort | Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Ipsilateral local recurrence (LR) | Defined as recurrent invasive or in situ cancer in the ipsilateral breast | 5 Year |
| Measure | Description | Time Frame |
|---|---|---|
| Ipsilateral invasive local recurrence | defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast | 5 Year |
| Breast cancer recurrence-free interval (RFI) |
Not provided
Inclusion Criteria:
Female patient > 45 years of age with DCIS without microinvasion.
Tumour size ≤ 2.5cm.
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
Not provided
Not provided
Not provided
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Brittany Speller | Contact | 905-527-2299 | 42611 | spelleb@mcmaster.ca |
| Daryl Hannah Soloman | Contact | 905-527-2299 | solomd5@mcmaster.ca |
| Name | Affiliation | Role |
|---|---|---|
| Eileen Rakovitch, M.D. | Sunnybrook Research Institute, Sunnybrook Health Science | Principal Investigator |
| Tim Whelan, M.D | Juravinski Cancer Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arthur J.E. Child Comprehensive Cancer Centre | Recruiting | Calgary | Alberta | T2N 5G2 | Canada |
Not provided
| Label | URL |
|---|---|
| TRACE/OCOG website accessed by clinical centres | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Specimens will be used to determine Oncotype DX DCIS Score and subsequent testing for future correlative studies
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer
| 5 Year |
| Distant disease-free survival (DDFS) | defined as time from study registration to distant recurrence | 5 Year |
| Disease-free survival (DFS) | defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause | 5 Year |
| Overall survival (OS) | defined as time from registration to death of any cause | 5 Year |
| Cross Cancer Institute | Recruiting | Edmonton | Alberta | T6G 1Z2 | Canada |
|
| BC Cancer - Abbotsford Centre | Recruiting | Abbotsford British Columbia | British Columbia | V2S 0C2 | Canada |
|
| BC Cancer - Centre for the North (Prince George) | Recruiting | Prince George | British Columbia | V2M 7E9 | Canada |
|
| BC Cancer - Fraser Valley Centre | Recruiting | Surrey | British Columbia | V3V 1Z2 | Canada |
|
| BC Cancer - Vancouver Centre | Recruiting | Vancouver | British Columbia | V5Z 4E6 | Canada |
|
| BC Cancer - Victoria | Recruiting | Victoria | British Columbia | V8R 6V5 | Canada |
|
| QE II HSC - Nova Scotia Cancer Centre | Recruiting | Halifax | Nova Scotia | B3H 1V7 | Canada |
|
| Cape Breton Cancer Centre | Recruiting | Sydney | Nova Scotia | B1P 1P3 | Canada |
|
| Royal Victoria Regional Health Centre | Recruiting | Barrie | Ontario | L4M 6M2 | Canada |
|
| Juravinski Cancer Centre | Recruiting | Hamilton | Ontario | L8V 5C2 | Canada |
|
| London Regional Cancer Program | Recruiting | London | Ontario | N6A 4L6 | Canada |
|
| Regional Cancer Care, Thunder Bay Regional Health Sciences Centre | Recruiting | Thunder Bay | Ontario | P7B 6V4 | Canada |
|
| Sunnybrook Health Science Centre -Odette Cancer Centre | Recruiting | Toronto | Ontario | M4N 3M5 | Canada |
|
| University Health Network - Princess Margaret Cancer Centre | Recruiting | Toronto | Ontario | M5G 2M9 | Canada |
|
| Windsor Regional Cancer Centre | Recruiting | Windsor | Ontario | N8W 2X3 | Canada |
|
| Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre) | Recruiting | Greenfield Park | Quebec | J4V 2H1 | Canada |
|
| CHUM - Centre Hospitalier de L'Université de Montréal | Recruiting | Montreal | Quebec | H2L 4M1 | Canada |
|
| Jewish General Hospital | Withdrawn | Montreal | Quebec | H3T 1E2 | Canada |
| McGill University Health Centre | Recruiting | Montreal | Quebec | H4A 3J1 | Canada |
|
| Centre intégré de cancérologie du CHU de Québec - Université Laval | Recruiting | Québec | Quebec | G1J 1Z4 | Canada |
|
| Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières | Recruiting | Trois-Rivières | Quebec | G8Z 3R9 | Canada |
|
| Allan Blair Cancer Centre | Recruiting | Regina | Saskatchewan | S4T 7T1 | Canada |
|
| Saskatoon Cancer Centre | Recruiting | Saskatoon | Saskatchewan | S7N4H4 | Canada |
|
| ID | Term |
|---|---|
| D002285 | Carcinoma, Intraductal, Noninfiltrating |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D000071960 | Breast Carcinoma In Situ |
| D002278 | Carcinoma in Situ |
| D018299 | Neoplasms, Ductal, Lobular, and Medullary |
Not provided
Not provided